There are relatively few data available on type II collagen disorders, and evidence is lacking on the disease course in relation to symptoms and development of complications, the level of actual disease burden over time as well as data to support identification of possible risk factors. This study aims to build a natural history data set through collection of a number of clinical, imaging, and laboratory assessments that may be specific predictors of type II collagen disorder progression and clinical outcome. Having a type II collagen disorder natural history data set can inform potential efficacy endpoints and biomarkers for future clinical trials. This natural history study will follow up to 60 individuals diagnosed with a type II collagen disorder for up to 3 years. Visits will be conducted every 3 months for the first year and then every 6 months, during which several assessments will be performed in order to learn about the natural course of the disease, including changes in clinical and functional outcomes, imaging and biofluid biomarkers. Some of the study activities include: a physical exam, height measurements, vision and breathing tests and x-ray. A blood sample will be collected once or twice each year. Most of the information collected, the tests done, and the schedule of visits in this study are the same as recommended for regular care of children with a type II collagen disorder.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Collection of relevant medical data (retrospective and prospective)
Timeframe: Up to 3 years
Anthropometric measurements
Timeframe: Up to 3 years
Change over time in motor function in children 2 years old and younger
Timeframe: Up to 2 years
Change over time in motor function in children >2 years old
Timeframe: Up to 3 years
Change over time in pulmonary function
Timeframe: Up to 3 years
Change over time in ophthalmological assessment
Timeframe: Up to 3 years
Change over time in skeletal abnormalities
Timeframe: Up to 3 years
Measurement of biomarkers for bone growth
Timeframe: Up to 3 years
Measurement of CNP/ProCNP
Timeframe: Up to 3 years
Measurement of bone-specific alkaline phosphatase (BALP)
Timeframe: Up to 3 years
Change in scores for the pediatric quality of life inventory parent report (PedsQL)
Timeframe: Up to 3 years
Change in PROMIS pediatric short form pain behaviors score
Timeframe: Up to 3 years
Change in fatigue
Timeframe: Up to 3 years